Institutes,Country,Name,Platform,Phase,In use,Date started,Reference,Listed by WHO,Listed by Milken,Other
Aegis Biodefense,USA,DNA vaccine,DNA,Pre-clinical,No,09/06/2020,Direct contact from company,no,no,NA
BioNet Asia,Thailand,COVIGEN,DNA,Phase I,No,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
Biosun Pharmed,Iran,DNA plasmid vaccine,DNA,Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Chula Vaccine Research Center,Thailand,DNA vaccine,DNA,Pre-clinical,No,31/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,DNA with electroporation
Ege University,Turkey,DNA vaccine,DNA,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Entos Pharmaceuticals,Canada,Covigenix VAX-001,DNA,Phase I/II,No,19/03/2020,https://www.pharmaceutical-business-review.com/news/entos-pharmaceuticals-fusogenix-covid-19/,yes,yes,NA
GeneOne Life Science,Republic of Korea/USA,GLS-5310,DNA,Phase I/II,No,27/08/2020,http://www.genels.com/en/sub/technology/vaccine.asp,no,no,NA
Genexine Consortium,Republic of Korea,GX-19,DNA,Phase I/II,No,16/03/2020,http://www.koreabiomed.com/news/articleView.html?idxno=7727,yes,yes,NA
Globe Biotech Ltd (DNA),Bangladesh,DNA plasmid vaccine,DNA,Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Immunomic Therapeutics Inc/Epivax Inc/PharmaJet,USA,DNA vaccine,DNA,Pre-clinical,No,09/04/2020,https://www.immunomix.com/immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform/,yes,yes,"Plasmid DNA, needle-free delivery"
Inovio Pharmaceuticals/International Vaccine Institute,USA/Republic of Korea,INO-4800,DNA,Phase II/III,No,12/03/2020,https://www.prnewswire.com/news-releases/inovio-receives-new-5-million-grant-to-accelerate-scale-up-of-smart-delivery-device-for-its-covid-19-vaccine-301022049.html,yes,yes,DNA plasmid vaccine electroporation device
Inserm,France,DNA vaccine,DNA,Pre-clinical,No,15/06/2020,https://presse.inserm.fr/en/covid-19-vaccine-research-at-inserm/39831/,yes,no,DNA immunostimulatory sequences
Karolinska Intitute/Cobra Biologics,Sweden,DNA vaccine,DNA,Pre-clinical,No,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,DNA with electroporation
Mediphage Bioceuticals/University of Waterloo,Canada,msDNA vaccine,DNA,Pre-clinical,No,16/04/2020,https://uwaterloo.ca/stories/news/university-waterloo-developing-dna-based-covid-19-vaccine,yes,yes,"Nasal spray, bacteriophage delivery, VLP-encoded DNA vaccine"
"National Institute of Chemistry, Slovenia",Slovenia,DNA plasmid vaccine,DNA,Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Plasmid DNA, nanostructured RBD"
"National Research Centre, Egypt (DNA)",Egypt,DNA plasmid vaccine,DNA,Pre-clinical,No,28/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"S,S1,S2,RBD &N "
OncoSec Medical Inc/Providence Cancer Institute,USA,CORVax12,DNA,Phase I,No,06/04/2020,https://ir.oncosec.com/press-releases/detail/2042/oncosec-collaborates-with-providence-cancer-institute-to,no,yes,Electroporated S plasmid DNA vaccine with or without electroporated IL-12p70 plasmid
Osaka University/AnGes/Takara Bio,Japan,AG0302-COVID19,DNA,Phase II/III,No,05/03/2020,https://www.anges.co.jp/en/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf,yes,yes,NA
Scancell/University of Nottingham/Nottingham Trent University,UK,DNA vaccine,DNA,Pre-clinical,No,24/04/2020,https://www.scancell.co.uk/Data/Sites/1/media/publications/news/covid-19-vaccine-programme.pdf,yes,yes,Target N and S proteins
Statens Serum Institute,Denmark,CoVAXIX,DNA,Pre-clinical,No,14/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,no,yes,NA
Symvivo,Canada,bacTRL-Spike,DNA,Phase I,No,06/04/2020,https://www.symvivo.com/covid-19,yes,yes,"Orally administered, genetically modified probiotic bacteria"
Takis/Applied DNA Sciences/Evvivax/Rottapharm Biotech,Italy/USA,COVID-eVax,DNA,Phase I/II,No,27/01/2020,http://www.takisbiotech.it/index.php/en/news/200-takis-and-evvivax-developing-a-2019-ncov-coronavirus-vaccine,yes,yes,NA
University of Cambridge/DIOSynVax,UK,DIOS-CoVax2,DNA,Pre-clinical,No,17/01/2020,https://www.cam.ac.uk/research/news/cambridge-research-team-working-towards-vaccine-against-covid-19,no,yes,NA
UW-Madison/Pan Genomes Systems,USA,DNA vaccine,DNA,Pre-clinical,No,15/02/2020,https://www.trialsitenews.com/uw-madison-spinoff-purses-covid-19-vaccine-introducing-pan-genome-systems/,no,no,Nasal spray; nucleic acid based
Vaccibody,Norway,VB10.COV2,DNA,Pre-clinical,No,01/04/2020,https://www.vaccibody.com/wp-content/uploads/2020/12/201210_PR_Vaccibody-Infectious-disease-strategy-and-CoV2-preclinical-data-FINAL.pdf,yes,no,DNA plasmid vaccine encoding RBD
Zydus Cadila Healthcare Limited (DNA),India,ZyCoV-D,DNA,Phase I/II,No,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,NA
Beijing Institute of Biological Products/Sinopharm,China,BBIBP-CorV,Inactivated,Phase IV,Yes,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
Bharat Biotech/ICMR/National Institute of Virology,India,Covaxin,Inactivated,Phase III,Yes,30/06/2020,https://timesofindia.indiatimes.com/city/hyderabad/indias-first-covid-19-vaccine-candidate-by-hyd-co-set-for-trials/articleshow/76699925.cms,yes,yes,NA
"Chumakov Center,/Russian Academy of Sciences",Russia,CoviVac,Inactivated,Pre-clinical,Yes,14/10/2020,https://tass.com/society/1212183,no,no,Inactivated whole-virion vaccine
Dynavax/PATH/GPO/Instituto Butantan/IVAC,USA/Thailand/Brazil/Vietnam,NDV-HXP-S,Inactivated,Phase I/II,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Whole chimeric NDV expressing membrane-anchored pre-fusion-stabilized trimeric SARS-CoV-2 S protein (Hexapro) + CpG 1018
Erciyes University (inactivated),Turkey,ERUCOV-VAC,Inactivated,Phase I,No,24/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",China,Inactivated vaccine,Inactivated,Phase III,No,17/04/2020,https://www.biocentury.com/article/304515,yes,yes,NA
KM Biologics,Japan,Inactivated vaccine,Inactivated,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Inactivated + alum
Kocak Farma Ilac Ve Kimya San. A.S.,Turkey,Inactivated vaccine,Inactivated,Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Milad Pharmaceuticals Co.,Uncertain,Inactivated vaccine,Inactivated,Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
"National Research Centre, Egypt (inactivated)",Egypt,Inactivated vaccine,Inactivated,Pre-clinical,No,29/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Inactivated whole virus 
Osaka University/BIKEN/NIBIOHN (inactivated),Japan,Inactivated vaccine,Inactivated,Pre-clinical,No,19/03/2020,https://pj.jiho.jp/article/241725,yes,yes,NA
Research Institute for/Biological Safety Problems (inactivated),Republic of Kazakhstan,QazCovid-in,Inactivated,Phase III,No,15/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Selcuk University (inactivated),Turkey,Inactivated vaccine,Inactivated,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Shenzhen Kangtai Biological Products Co Ltd,China,Inactivated vaccine,Inactivated,Phase II,No,27/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Shifa Pharmed,Iran,Inactivated vaccine,Inactivated,Phase I,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Sinovac,China/Brazil,CoronaVac,Inactivated,Phase IV,Yes,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,Formaldehyde-inactivated + alum
Sinovac/Dynavax,China/USA,Inactivated vaccine,Inactivated,Pre-clinical,No,16/04/2020,https://www.globenewswire.com/news-release/2020/04/16/2017222/0/en/Dynavax-and-Sinovac-Announce-Collaboration-to-Develop-a-Coronavirus-COVID-19-Vaccine.html,yes,yes,Sinovac’s inactivated vaccine plus Dynavax adjuvant CpG 1018 adjuvant
Valneva/Dynavax,Austria/USA,VLA2001,Inactivated,Phase I/II,No,22/04/2020,https://valneva.com/press-release/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19/,yes,yes,NA
Wuhan Institute of Biological Products/Sinopharm,China,WIBP vaccine,Inactivated,Phase III,Yes,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
Zista Kian Azma Co.,Uncertain,Inactivated vaccine,Inactivated,Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Codagenix/Serum Institute of India,USA/India,COVI-VAC,Live-attenuated,Phase I,No,13/02/2020,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html?tc=eml_cleartime,yes,yes,Codon deoptimized live attenuated vaccines
Indian Immunologicals Ltd/Griffith University,India/USA,Live-attenuated vaccine,Live-attenuated,Pre-clinical,No,23/04/2020,https://news.griffith.edu.au/2020/04/23/griffith-university-researchers-on-the-road-to-covid-19-vaccine/,yes,yes,Codon deoptimized live attenuated virus
Mehmet Ali Aydinlar University/Abicadem Labmed Health Services,Turkey,Live-attenuated vaccine,Live-attenuated,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Codon deoptimized live attenuated vaccines
Meissa Vaccines,USA ,MV-014-210,Live-attenuated,Pre-clinical,No,30/06/2020,https://www.businesswire.com/news/home/20200630005072/en/Meissa-Vaccines-Pipeline-Update-Vaccine-Candidates-COVID-19,no,yes,NA
Aivita Biomedical Inc,USA,AV-COVID-19,Other,Phase I,No,13/05/2020,https://clinicaltrials.gov/ct2/show/NCT04386252,no,no,NA
AlyraBio/TheRex,France,Replicating bacterial vector vaccine,Other,Pre-clinical,No,16/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Cell Tech Pharmed (other),Iran,Cell-based vaccine,Other,Pre-clinical,No,26/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Engineered mesenchymal stem cells transfected with plasmid expressing S and N
COVID-19 Vaccine Corporation Ltd,New Zealand,Biodegradable polymer biobead display vaccine,Other,Pre-clinical,No,01/05/2020,https://cvc.nz,no,no,2 antigens: RBD and multiple T cell epitopes
ERC Worldwide,Belgium,ERC SARS-Cov-2 vaccine,Other,Pre-clinical,No,09/04/2020,https://finance.yahoo.com/news/erc-launches-development-program-novel-120010871.html,no,no,Consists of virions at different stages of viral replication and human cells/fragments
Farmacológicos Veterinarios SAC/Universidad Peruana Cayetano Heredia/(bacterial vector),Peru,Replicating bacterial vector vaccine,Other,Pre-clinical,No,28/08/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Oral Salmonella enteritidis (3934Vac) based protein expression system of RBD
Institut Pasteur Lille/Inserm,France,Replicating bacterial vector vaccine,Other,Pre-clinical,No,15/06/2020,https://presse.inserm.fr/en/covid-19-vaccine-research-at-inserm/39831/,yes,no,Pertussis vector exprossing SARS-CoV-2 antigens
OSE immunotherapeutics,France,CoVepiT,Other,Pre-clinical,No,02/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,"CD8 T cell peptide targeting(S, M, N) and (NSPs) SARS-CoV-2 proteins"
Shenzhen Geno-Immune Medical Institute/(modified APC),China,aAPC vaccine,Other,Phase I,No,31/01/2020,https://www.nature.com/articles/d41573-020-00073-5,no,yes,Artificial APCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins
Shenzhen Geno-Immune Medical Institute/(modified DC),China,LV-SMENP-DC vaccine,Other,Phase I/II,No,31/01/2020,https://www.nature.com/articles/d41573-020-00073-5,no,yes,DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs
Ufovax,USA,1c-SApNP VLP vaccine,Other,Pre-clinical,No,12/04/2020,https://statnano.com/news/67566/Ufovax-Formulates-COVID-19-Vaccine-Using-its-Nanoparticle-Vaccine-Technology,no,no,NA
"University of California, Los Angeles",USA,Replicating bacterial vector vaccine,Other,Pre-clinical,No,01/05/2020,http://ucla.technologypublisher.com/techcase/20-0322,no,yes,Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens.
Versatope/Umass (OMV),USA,rOMV vaccine,Other,Pre-clinical,No,30/03/2020,https://www.uml.edu/News/stories/2020/M2D2-coronavirus-efforts.aspx?mc_cid=b01e8bd49c&mc_eid=565cb5181a,no,no,Recombinant outer membrane vesicles displaying spike protein
Voltron Therapeutics/Hoth Therapeutics/Massachusetts General Hospital,USA,HaloVax,Other,Pre-clinical,No,27/03/2020,https://www.biospace.com/article/releases/halovax-announces-agreement-with-hoth-therapeutics-to-joint-develop-a-self-assembling-vaccine-sav-to-protect-patients-at-risk-of-coronavirus-covid-19-infection/,no,yes,VaxCelerate platform
AdaptVac,Denmark,Capsid-like particle vaccine,Protein subunit,Pre-clinical,No,09/03/2020,https://www.medizin.uni-tuebingen.de/files/view/W0nPpDMa6lLgzbJo9VGLXAbO/200309%20Press%20release%20Covid-19%20consortium_final.pdf,yes,yes,Capsid-like particle
Adimmune Corporation,Taiwan,AdimrSC-2f,Protein subunit,Phase I,No,09/03/2020,https://www.taiwannews.com.tw/en/news/3894294,no,no,RBD produced by baculovirus-insect cell expression system; administered with/without aluminum content as adjuvant
AJ Vaccines,Denmark,Protein subunit vaccine,Protein subunit,Pre-clinical,No,06/03/2020,https://ajvaccines.com/news/,yes,yes,S protein
Akdeniz University,Turkey,Protein subunit vaccine,Protein subunit,Pre-clinical,No,19/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,"Recombinant protein S1, S2, and N subunits using plant expression vector"
Akers Biosciences/Premas Biotech ,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,08/04/2020,https://www.biospace.com/article/releases/akers-biosciences-and-premas-biotech-announce-successful-expression-of-coronavirus-antigens/,no,no,"Spike (S), Envelope (E) and Membrane (M) proteins"
Akston Biosciences/University Medical Center Groningen,USA/Netherlands,AKS-452,Protein subunit,Phase I/II,No,01/09/2020,http://www.globenewswire.com/news-release/2020/09/01/2087205/0/en/TRACER-to-support-Akston-Biosciences-Phase-1-clinical-study-of-AKS-452-an-innovative-anti-COVID-19-vaccine.html,no,no,SARS-CoV-2-RBD-Fc fusion protein
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,China,ZF2001,Protein subunit,Phase III,No,02/03/2020,http://hefeihightech.chinadaily.com.cn/2020-03/02/c_459323.htm,yes,yes,Adjuvanted recombinant protein (RBD-Dimer)
AnyGo Technology,China,Protein subunit vaccine,Protein subunit,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Protein subunit, recombinant S1-Fc fusion protein"
Applied Biotechnology Institute Inc,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Orally delivered, heat stable subunit"
Arizona State University (subunit),USA,NYVAC-KC,Protein subunit,Pre-clinical,No,19/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Attenuated vaccinia virus vector expressing S and other viral proteins
Ataturk University/Health Institutes of Turkey (TUSEB),Turkey,Protein subunit vaccine,Protein subunit,Pre-clinical,No,19/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Recombinant protein vaccine
Axon Neuroscience SE,Slovakia,Peptide vaccine,Protein subunit,Pre-clinical,No,09/04/2020,https://www.biospace.com/article/releases/axon-neuroscience-has-a-promising-peptide-vaccine-against-covid-19-in-development/,yes,yes,NA
Baiya Phytopharm/Chula Vaccine Research Center,Thailand,Plant-based vaccine,Protein subunit,Pre-clinical,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Plant-based subunit; RBD-Fc + Adjuvant
Baylor College of Medicine,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,S1 or RBD protein
BioFarma/Eijkman Institute for Molecular Biology,Indonesia,Merah Putih,Protein subunit,Pre-clinical,No,14/08/2020,https://en.antaranews.com/news/154250/bio-farma-projected-covid-19-vaccine-merah-putih-roll-out-by-2022,no,no,Recombinant forms of the S sub-units and N protein
Biological E Ltd,India,BECOV,Protein subunit,Phase I/II,No,11/04/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,Adjuvanted protein subunit (RBD)
BiOMVis Srl/University of Trento,Italy,OMV-based vaccine,Protein subunit,Pre-clinical,No,15/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,OMV-based vaccine
Bogazici University,Turkey,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Peptide + novel adjuvant
CEA/CNRS,France,Protein subunit vaccine,Protein subunit,Pre-clinical,No,16/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Protein subunit adnoviral carrier
Center for Advanced Technologies,Uzbekistan,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/02/2021,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Soluble recombinant S protein produced in CHO cells
Center for Genetic Engineering/and Biotechnology (peptide #1),Cuba,CIGB-66,Protein subunit,Phase I/II,No,01/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,"RBD + aluminium hydroxide; intramuscular prime, intranasal boost"
Center for Genetic Engineering/and Biotechnology (peptide #2),Cuba,CIGB-669,Protein subunit,Phase I/II,No,01/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,"RBD + AgnHB; intramuscular prime, intranasal boost"
Chulalongkorn University/GPO,Thailand,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,RBD protein fused with Fc of IgG + Adjuvant
Clover Biopharmaceuticals Inc/GSK/Dynavax,China/UK/USA,SCB-2019,Protein subunit,Phase II/III,No,24/02/2020,https://www.businesswire.com/news/home/20200224005319/en,yes,yes,Native-like trimeric subunit spike protein vaccine
Covaxx/United Biomedical Inc,USA,UB-612,Protein subunit,Phase II/III,No,15/07/2020,https://www.covaxx.com/press-release-jul15-1,no,yes,Multitope peptide-based Vaccine 
EpiVax,USA,EPV-CoV-19,Protein subunit,Pre-clinical,No,27/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
EpiVax/University of Georgia,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,04/03/2020,https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology,yes,yes,S protein
EuBiologics Co Ltd,Republic of Korea,EuCorVac-19,Protein subunit,Phase I/II,No,25/02/2021,http://www.eubiologics.com/eng/sub4_2_view.php?idx=14&page_number=1&mode=&search_gubun=all&search_keyword=,yes,no,Spike protein using recombinant protein technology with adjuvant
ExpreS2ion,Denmark,Protein subunit vaccine,Protein subunit,Pre-clinical,No,06/03/2020,"https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-eu-grant-award-for-the-covid-19-vaccine-development-programme,c3054055",yes,yes,Drosophila S2 insect cell expression system and AdaptVac capsid VLPs
Farmacológicos Veterinarios SAC/Universidad Peruana Cayetano Heredia/(subunit),Peru,Protein subunit vaccine,Protein subunit,Pre-clinical,No,28/08/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,RBD protein (baculovirus production) + FAR-Squalene adjuvant
Flow Pharma Inc,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,NA
G+Flas Life Sciences,Republic of Korea,Plant-based vaccine,Protein subunit,Pre-clinical,No,01/04/2020,http://www.biospectator.com/view/news_view.php?varAtcId=9750,no,no,NA
Generex/EpiVax,USA/Canada,Ii-Key peptide vaccine,Protein subunit,Pre-clinical,No,27/02/2020,https://www.globenewswire.com/news-release/2020/02/27/1992098/0/en/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html,yes,yes,NA
Hacettepe University,Turkey,Protein subunit vaccine,Protein subunit,Pre-clinical,No,19/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Peptides with alum
Heat Biologics/University Of Miami,USA,gp-96 vaccine,Protein subunit,Pre-clinical,No,05/03/2020,https://www.heatbio.com/news-media/news-releases/detail/649/heat-biologics-announces-research-collaboration-with,yes,yes,NA
Helix Biogen Consult/Ogbomoso & Trinity Immonoefficient/Laboratory,Nigeria ,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/06/2020,https://www.pulse.ng/news/local/covid-19-nigerian-scientists-working-on-preventive-vaccines-call-for-assistance/x256s7z,yes,yes,NA
iBio/CC-Pharming,USA/China,Protein subunit vaccine,Protein subunit,Pre-clinical,No,03/02/2020,https://www.globenewswire.com/news-release/2020/02/03/1979068/0/en/iBio-and-CC-Pharming-Initiate-Joint-Development-of-Coronavirus-Vaccine.html,yes,yes,"Subunit protein, plant produced"
ImmunoPrecise/LiteVax BV,Canada,Protein subunit vaccine,Protein subunit,Pre-clinical,No,20/02/2020,https://pipelinereview.com/index.php/2020022173854/Antibodies/ImmunoPrecise-Launches-Coronavirus-Vaccine-and-Therapeutic-Antibody-Program.html,yes,yes,NA
IMV Inc,USA,DPX-COVID-19,Protein subunit,Pre-clinical,No,30/03/2020,https://ir.imv-inc.com/press-releases/detail/638/imv-inc-provides-updates-on-the-development-of,yes,yes,Peptide antigens formulated in lipid nanoparticle formulation
InnoMedica,Switzerland,TaliCoVax19,Protein subunit,Pre-clinical,No,19/04/2020,https://www.innomedica.com/en/2020/03/30/march-2020-innomedica-launches-project-for-corona-vaccination/,no,yes,RBD protein expressed from bacteria + liposome carrier system
Innovax/Xiamen University/GSK,China/UK,COVID-19 XWG-03,Protein subunit,Pre-clinical,No,03/04/2020,https://www.fiercebiotech.com/biotech/gsk-allies-innovax-for-covid-19-vaccine-r-d-project,yes,yes,Truncated S (spike) proteins
Instituto Finlay de Vacunas (peptide #1),Cuba,FINLAY-FR-1/Soberana 1,Protein subunit,Phase I/II,No,01/08/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,no,no,RBD + adjuvant
Instituto Finlay de Vacunas (peptide #2),Cuba,FINLAY-FR-2/Soberana 2,Protein subunit,Phase II,No,01/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,rRBD produced in CHO-cell chemically conjugate to tetanus toxoid
Intravacc/Epivax (peptide),Netherlands/USA,OMV-peptide vaccine,Protein subunit,Pre-clinical,No,14/05/2020,https://www.intravacc.nl/,yes,yes,NA
Intravacc/Epivax (subunit),Netherlands/USA,OMV-subunit vaccine,Protein subunit,Pre-clinical,No,14/05/2020,https://www.intravacc.nl/,yes,yes,NA
Izmir Biomedicine and Genome Center,Turkey,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Kazakh National Agrarian University,Republic of Kazakhstan,Protein subunit vaccine,Protein subunit,Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Kentucky Bioprocessing Inc,USA,KBP-COVID-19,Protein subunit,Phase I/II,No,02/04/2020,https://www.kentucky.com/news/coronavirus/article241709386.html,yes,yes,Biotech subsidiary of British American Tobacco
LakePharma Inc,USA,"Protein subunit, nanoparticle vaccine",Protein subunit,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Nanoparticle vaccine
Liaoning Chengda Biotechnology/Tsinghua University,China,Peptide vaccine,Protein subunit,Pre-clinical,No,17/04/2020,https://www.bioworld.com/COVID19products,no,no,NA
LinkinVax/Vaccine Research Institute/Inserm,France,Protein subunit vaccine,Protein subunit,Pre-clinical,No,15/06/2020,https://presse.inserm.fr/en/covid-19-vaccine-research-at-inserm/39831/,yes,no,Protein DC-targeted epitopes
Lomonosov Moscow State University ,Russia,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Structurally modified spherical particles of the tobacco mosaic virus (TMV) 
Marmara University,Turkey,Protein subunit vaccine,Protein subunit,Pre-clinical,No,19/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Recombinant S encoded by baculoviruses in insect cells
Max Planck Institute of/Colloids and Interfaces (subunit),Germany,Protein subunit vaccine,Protein subunit,Pre-clinical,No,13/05/2020,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,no,yes,S protein plus targeting ligand for Langerhans cells
Medigen Vaccine Biologics Corporation/NAID/Dynavax,Taiwan/USA,MVC-COV1901,Protein subunit,Phase II,No,17/02/2020,https://www.pharmashots.com/press-releases/taiwan-firm-teams-up-with-us-to-develop-covid-19-vaccine/,yes,yes,S-2 P protein + CpG 1018
MIGAL Galilee Research Institute,Israel,Protein subunit vaccine,Protein subunit,Pre-clinical,No,27/02/2020,http://www.migal.org.il/Migal.covid,yes,yes,Oral E. coli-based protein expression system of S and N proteins
MOGAM Institute for Biomedical Research/GC Pharma,Republic of Korea,Protein subunit vaccine,Protein subunit,Pre-clinical,No,19/03/2020,http://www.businesskorea.co.kr/news/articleView.html?idxno=42991,yes,yes,Synthetic antigen-based ubunit vaccine
Mynvax,India,Protein subunit vaccine,Protein subunit,Pre-clinical,No,15/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Nanogen Biopharmaceutical,Vietnam,Nanocovax,Protein subunit,Phase I/II,No,01/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,"Recombinant S protein, aluminum adjuvanted"
National Institute of Infectious Disease/Shionogi/UMN Pharma,Japan,Protein subunit vaccine,Protein subunit,Pre-clinical,No,11/04/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,S protein + adjuvant
"National Research Centre, Egypt (subunit)",Egypt,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Protein Subunit S,N,M&S1 protein "
Neo7Logix,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Neovii/Tel Aviv University,Israel,RBD-based vaccine,Protein subunit,Pre-clinical,No,13/05/2020,https://neovii.com/neovii-partners-with-tel-aviv-university-to-develop-novel-covid-19-vaccine/,yes,yes,RBD-based 
Novavax,USA,NVX-CoV2373,Protein subunit,Phase III,No,10/03/2020,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,yes,yes,VLP-recombinant protein nanoparticle vaccine + Matrix M
Ohio State University/Kazakh National Agrarian University,USA/Republic of Kazakhstan,Protein subunit vaccine,Protein subunit,Pre-clinical,No,25/07/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,RBD protein delivered in mannose- conjugated chitosan nanoparticle
OncoGen,Romania,Protein subunit vaccine,Protein subunit,Pre-clinical,No,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,Synthetic long peptide vaccine candidate for S and M proteins
Osaka University/BIKEN/NIBIOHN (subunit),Japan,VLP-recombinant protein vaccine,Protein subunit,Pre-clinical,No,11/04/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,VLP-recombinant protein + adjuvant
PDS Biotechnology,USA,PDS0203,Protein subunit,Pre-clinical,No,16/04/2020,https://www.globenewswire.com/news-release/2020/04/16/2017301/0/en/PDS-Biotechnology-Initiates-Novel-Vaccine-Development-Programs-For-COVID-19-and-Universal-Influenza-Delay-of-PDS0101-VERSATILE-002-trial.html,no,yes,Versamune T-cell activating technology with Sars-CoV-2 antigens
Quadram Institute Biosciences,UK,OMV-based vaccine,Protein subunit,Pre-clinical,No,07/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Bacterial extracellular vesicle (BEV)-based mucosal vaccine. 
Razi Vaccine and Serum/Research Institute,Iran,Razi Cov Pars,Protein subunit,Phase I,No,18/01/2021,https://www.tehrantimes.com/news/457063/Second-Iranian-made-coronavirus-vaccine-receives-clinical-trial,no,yes,Recombinant Spike protein
Research Institute for/Biological Safety Problems (subunit),Republic of Kazakhstan,Protein subunit vaccine,Protein subunit,Pre-clinical,No,31/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Sanofi Pasteur/GSK,France/UK,VAT00002,Protein subunit,Phase III,No,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,S protein (baculovirus production)
Shionogi,Japan,S-268019,Protein subunit,Phase I/II,No,01/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Recombinant protein vaccine using Baculovirus expression vector system
SK Biosciences,Republic of Korea,NBP2001,Protein subunit,Phase I,No,24/11/2020,https://www.koreabiomed.com/news/articleView.html?idxno=9722,no,no,Recombinant subunit vaccine targeting RBD
SK Biosciences,Republic of Korea,GBP510,Protein subunit,Phase I/II,No,23/03/2020,http://www.koreabiomed.com/news/articleView.html?idxno=7798,no,yes,NA
Soligenix Inc/University of Hawaiʻi at Mānoa,USA,CiVax,Protein subunit,Pre-clinical,No,28/07/2020,https://www.prnewswire.com/news-releases/soligenix-announces-publication-of-positive-pre-clinical-results-for-a-novel-covid-19-vaccine-301100798.html,no,no,Heat-stable subunit vaccine with CoVaccine adjuvant
Sorbonne University,France,Protein subunit vaccine,Protein subunit,Pre-clinical,No,16/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Sorrento Therapeutics,USA,T-VIVA-19,Protein subunit,Pre-clinical,No,17/08/2020,https://sorrentotherapeutics.com/research/covid-19/t-viva-19/,no,yes,Recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc (T-VIVA-19)
St Petersburg Scientific Research Institute/of Vaccines and Sera,Russia,Protein subunit vaccine,Protein subunit,Pre-clinical,No,11/04/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,"Recombinant protein, nanoparticles (based on S-protein and other epitopes)"
Tampere University (subunit),Finland,Protein subunit vaccine,Protein subunit,Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Recombinant S protein produced in BEVS
University Hospital Tübingen,Germany,CoVac-1,Protein subunit,Phase I,No,01/09/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,SARS-CoV-2 HLA-DR peptides
University of Alberta,Canada,Protein subunit vaccine,Protein subunit,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Spike based
"University of California, San Diego",USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,20/04/2020,https://ucsdnews.ucsd.edu/pressrelease/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine,no,yes,Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch
University of Pittsburgh,USA,PittCoVacc,Protein subunit,Pre-clinical,No,02/04/2020,https://www.upmc.com/media/news/040220-falo-gambotto-sars-cov2-vaccine,yes,yes,Microneedle arrays S1 subunit
University of Queensland/CSL/Seqirus,Australia/UK/USA,Molecular clamp vaccine,Protein subunit,Terminated,No,24/01/2020,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,yes,yes,"Molecular clamp stabilized spike protein, CSL MF59 adjuvant"
University of San Martin/CONICET,Argentina,Protein subunit vaccine,Protein subunit,Pre-clinical,No,12/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
University of Virginia,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,S subunit intranasal liposomal formulation with GLA/3M052 adjuvants
Vabiotech,Vietnam,IC-BEVS,Protein subunit,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Protein subunit, recombinant S protein in IC-BEVS  "
Vaxil Bio,Israel,Protein subunit vaccine,Protein subunit,Pre-clinical,No,13/02/2020,https://pipelinereview.com/index.php/2020021673805/Vaccines/Vaxil-Announces-the-Identification-of-a-Potential-Corona-Virus-Vaccine-and-Provides-an-Update-in-the-Previously-Announced-Debt-Financing.html,yes,yes,NA
Vaxinano/CEA/INRAE,France,Protein subunit vaccine,Protein subunit,Pre-clinical,No,16/04/2020,http://www.vaxinano.com/news-32.html,yes,no,NA
Vaxine Pty/Medytox,Australia,COVAX-19,Protein subunit,Phase I,No,03/04/2020,https://news.flinders.edu.au/blog/2020/04/03/flinders-targets-covid-19-vaccine/,yes,yes,Recombinant spike protein with Advax™ adjuvant
Vector Institute (peptide),Russia,EpiVacCorona,Protein subunit,Phase III,Yes,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Peptide vaccine
Vector Institute (subunit),Russia,Protein subunit vaccine,Protein subunit,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Subunit vaccine
Versatope/Umass (subunit),USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,30/03/2020,https://www.uml.edu/News/stories/2020/M2D2-coronavirus-efforts.aspx?mc_cid=b01e8bd49c&mc_eid=565cb5181a,no,no,Polypeptide-based
"VIDO-InterVac,/University of Saskatchewan",Canada,COVAC,Protein subunit,Phase I/II,No,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,NA
Walter Reed Army Institute of Research,USA,SpFN,Protein subunit,Phase I,No,16/10/2020,https://www.army.mil/article/240023/wrair_announces_covid_19_vaccine_candidate_targets_clinical_trial_date,yes,yes,Spike ferritin nanoparticle with a liposomal formulation QS21 (ALFQ) adjuvant
Walter Reed Army Institute of Research/USAMRIID,USA,Protein subunit vaccine,Protein subunit,Pre-clinical,No,05/03/2020,https://www.defense.gov/Newsroom/Transcripts/Transcript/Article/2104736/defense-department-press-briefing-investigating-and-developing-vaccine-candidat/,yes,yes,S protein
"West China Hospital,/Sichuan University",China,Protein subunit vaccine,Protein subunit,Phase II,No,28/08/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,RBD (baculovirus production expressed in Sf9 cells)
Yildiz Technical University,Turkey,Protein subunit vaccine,Protein subunit,Pre-clinical,No,19/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Adjuvanted peptides + recombinant S
Yisheng Biopharma,China,Protein subunit vaccine,Protein subunit,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Arcturus/Duke-NUS,USA/Singapore,LUNAR-COV19/ARCT-021,RNA,Phase II,No,04/03/2020,https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-and-duke-nus-medical-school-partner,yes,yes,NA
BIOCAD,Russia,RNA vaccine,RNA,Pre-clinical,No,19/03/2020,https://biocadglobal.com/index.php?posts&post=45,yes,yes,NA
BioNTech/Pfizer/Fosun Pharma,Germany/USA,BNT162,RNA,Phase IV,Yes,17/03/2020,https://www.businesswire.com/news/home/20200316005943/en/,yes,yes,NA
Cansino Biologics/Precision Nanosystems,China/Canada,RNA vaccine,RNA,Pre-clinical,No,20/05/2020,https://www.precisionnanosystems.com/our-company/news-room/detail/cansino-biologics-and-precision-nanosystems-announce-collaboration-to-co-develop-a-covid-19-rna-vaccine,yes,yes,LNP-mRNA
CEA,France,RNA vaccine,RNA,Pre-clinical,No,16/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Encapsulated mRNA
Cell Tech Pharmed (RNA),Iran,mRNA vaccine,RNA,Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Centro Nacional Biotecnología (CNB-CSIC)/(RNA),Spain,RNA vaccine,RNA,Pre-clinical,No,26/03/2020,https://fems-microbiology.org/wp-content/uploads/2020/03/Enjuanes-Sola-Zúñiga-2020.-Novel-Human-Pathogenic-Coronavirus-SARS-CoV-2.pdf,yes,yes,Replicating defective SARS-CoV-2 derived RNAs
Chimeron Bio/George Mason University ,USA,RNA vaccine,RNA,Pre-clinical,No,28/05/2020,https://www.businesswire.com/news/home/20200528005481/en/Chimeron-Bio-George-Mason-University%E2%80%99s-National-Center,no,yes,NA
China CDC/Tongji University/Stermina Therapeutics,China,RNA vaccine,RNA,Pre-clinical,No,17/03/2020,https://news.cgtn.com/news/2020-03-17/Shanghai-announces-steady-progress-in-COVID-19-vaccine-development--OVydZfNUFG/index.html,yes,yes,NA
Chula Vaccine Research Center/University of Pennsylvania,Thailand/USA,ChulaCov19,RNA,Phase I/II,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,LNP-mRNA 
CureVac,Germany/USA,CVnCoV,RNA,Phase III,No,03/03/2020,https://www.curevac.com/news/curevac-ceo-daniel-menichella-berät-mit-us-präsident-donald-trump-und-mitgliedern-der-corona-task-force-entwicklungsmöglichkeiten-eines-coronavirus-impfstoffes,yes,yes,NA
Elixirgen Therapeutics/Fujita Health University,USA,EXG-5003,RNA,Pre-clinical,No,04/06/2020,https://elixirgentherapeutics.com/news/fda/elixirgen-therapeutics-concludes-pre-ind-meeting-with-fda-for-its-covid-19-vaccine-candidate-exg-5003,no,yes,NA
Emergex Vaccines/George Mason University,UK/USA,RNA vaccine,RNA,Pre-clinical,No,22/04/2020,https://emergexvaccines.com/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies/,no,yes,NA
eTheRNA Immunotherapies,Belgium,mRNA TriMix vaccine,RNA,Pre-clinical,No,24/03/2020,https://www.thepharmaletter.com/article/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine,yes,yes,Intranasal
Fudan University/Shanghai JiaoTong University/RNACure Biopharma (VLP),China/USA,RNA vaccine (encoding VLP),RNA,Pre-clinical,No,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,LNP-encapsulated mRNA cocktail encoding VLP
Fudan University/Shanghai JiaoTong University/RNACure Biopharma/(RBD),China/USA,RNA vaccine (encoding RBD),RNA,Pre-clinical,No,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,LNP-encapsulated mRNA encoding RBD
GeneOne Life Science/Houston Methodist,Republic of Korea/USA,GLS-3000,RNA,Pre-clinical,No,17/03/2020,https://www.houstonmethodist.org/research/covid19/geneone/,no,yes,NA
Gennova,India,Self-amplifying RNA vaccine,RNA,Pre-clinical,No,15/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Globe Biotech Ltd (RNA),Bangladesh,mRNA vaccine,RNA,Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,D614G variant LNP-encapsulated mRNA
Greenlight Biosciences,USA,RNA vaccine,RNA,Pre-clinical,No,05/05/2020,https://www.greenlightbiosciences.com/covid19/,yes,yes,NA
GSK,UK,CoV-2 SAM LNP,RNA,Phase I,No,20/07/2020,https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-announce-strategic-mrna-technology-collaboration/,no,no,Self-amplifying mRNA (SAM) lipid nanoparticle platform targeting S
IDIBAPS-Hospital Clinic (RNA),Spain,mRNA vaccine,RNA,Pre-clinical,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Imperial College London,UK,LNP-nCoVsaRNA,RNA,Terminated,No,15/01/2020,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid-19-vaccine/,yes,yes,NA
Infectious Disease Research Institute/Amyris Inc,USA,saRNA vaccine,RNA,Pre-clinical,No,27/07/2020,https://investors.amyris.com/2020-07-27-Amyris-and-The-Infectious-Disease-Research-Institute-Partner-to-Advance-Novel-RNA-Vaccine-Platform-Beginning-With-COVID-19-Application,yes,no,saRNA formulated in a NLC
Max Planck Institute of/Colloids and Interfaces (RNA),Germany,RNA vaccine,RNA,Pre-clinical,No,13/05/2020,https://www.mpg.de/14807464/0511-mpin-116799-corona-vaccination-via-the-skin,no,yes,S mRNA plus targeting ligand for Langerhans cells
Medigen Vaccine Biologics Corporation/Vaxess Technologies,Taiwan/USA,RNA vaccine,RNA,Pre-clinical,No,29/01/2021,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,"Recombinant, pre-fusion stabilised S antigens"
Moderna/NIAID,USA,mRNA-1273,RNA,Phase IV,Yes,13/01/2020,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,yes,yes,LNP-encapsulated mRNA
Moderna/NIAID (B.1.351),USA,mRNA-1273.351,RNA,Phase I,No,24/02/2021,https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine,yes,yes,LNP-encapsulated mRNA targeting variant B.1.351
Providence Therapeutics,USA,PTX-COVID19-B,RNA,Phase I,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
ReNAP Co.,Unknown,mRNA vaccine,RNA,Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
RNAimmune Inc,USA,RNA vaccine,RNA,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Rochester Clinical Research,USA,RNA vaccine,RNA,Pre-clinical,No,05/05/2020,https://www.rcrclinical.com/clinical-trial/coronavirus-vaccine-interest-list/,no,no,NA
Selcuk University (RNA),Turkey,mRNA vaccine,RNA,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Shulan (Hangzhou) Hospital/Guangxi Zhuang Autonomous Region CDC/PLA Academy of Military Sciences/Walvax Biotech,China,ARCoV,RNA,Phase I,No,17/04/2020,https://www.biocentury.com/article/304515,yes,yes,NA
Translate Bio/Sanofi Pasteur,France/USA,LNP-mRNA vaccine,RNA,Pre-clinical,No,27/03/2020,https://investors.translate.bio/news-releases/news-release-details/sanofi-pasteur-and-translate-bio-collaborate-develop-novel-mrna,yes,yes,NA
University of Tokyo/Daiichi-Sankyo,Japan,LNP-encapsulated mRNA vaccine,RNA,Pre-clinical,No,11/04/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,NA
University of Washington/NIH/HDT Bio Corp,USA,HDT-301,RNA,Pre-clinical,No,13/02/2020,https://newsroom.uw.edu/news/covid-19-vaccine-has-robust-response-nonhuman-primates,no,no,NA
Vector Institute (RNA),Russia,RNA vaccine,RNA,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Ziphius Therapeutics/Ghent University,Belgium,ZIP-1642,RNA,Pre-clinical,No,20/03/2020,https://7dffaa19-682b-4760-bc5a-592e63dfdd3b.filesusr.com/ugd/bc1b8f_b6bf5b2e693b4a14aaa51084089eb95c.pdf,no,yes,mRNA encoding multiple SARS-CoV-2 antigens
AbVision,USA,AVI-205,Unknown,Pre-clinical,No,03/05/2020,http://abvisioninc.com/2020/05/03/abvision-announced-a-first-in-class-active-targeting-vaccine-candidate-for-covid-19/,no,yes,NA
Adeleke University,Nigeria ,Unnamed vaccine,Unknown,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,no,yes,NA
Boryung Biopharma,Republic of Korea,Unnamed vaccine,Unknown,Pre-clinical,No,09/03/2020,http://www.koreabiomed.com/news/articleView.html?idxno=7650,no,no,NA
"Catholic University,/Millennium Institute of Immunology &/Immunotherapy",Chile,Unnamed vaccine,Unknown,Pre-clinical,No,13/03/2020,https://translate.google.com/translate?hl=en&sl=es&tl=en&u=http%3A%2F%2Fwww.imii.cl%2Fcientificos-chilenos-trabajan-desarrollo-vacuna-coronavirus-preparacion-la-pandemia%2F,no,yes,NA
Changchun Zhuoyi Biological,China,Unnamed vaccine,Unknown,Pre-clinical,No,17/04/2020,https://www.biocentury.com/article/304515,no,no,NA
Chongqing Zhifei Biological Products/Chinese Academy of Sciences,China,Unnamed vaccine,Unknown,Pre-clinical,No,17/04/2020,https://www.biocentury.com/article/304515,no,no,NA
Codiak BioSciences/Ragon Institute,USA,Unnamed vaccine,Unknown,Pre-clinical,No,01/06/2020,https://www.businesswire.com/news/home/20200601005079/en/Codiak-BioSciences-Collaborates-Ragon-Institute-Evaluate-exoVACC%E2%84%A2,no,yes,exoVACC exome platform
Hualan Biological Engineering,China,Unnamed vaccine,Unknown,Pre-clinical,No,17/04/2020,https://www.biocentury.com/article/304515,no,no,NA
ISR Immune System Regulation,Sweden,ISR-50,Unknown,Pre-clinical,No,19/03/2020,http://israb.se/pressdetalj/?id=http://publish.ne.cision.com/v2.0/Release/GetDetail/6C15E245715A57C0,no,yes,NA
Nidovax,USA,Unnamed vaccine,Unknown,Pre-clinical,No,28/06/2020,https://www.nidovax.com/,no,yes,IMT504 technology
Oragenics,USA,TerraCoV2,Unknown,Pre-clinical,No,04/05/2020,https://www.oragenics.com/news-media/press-releases/detail/104/oragenics-acquires-noachis-terra-inc-to-develop-its,no,yes,NA
"Precision Vaccines Program,/Boston Children's Hospital",USA,Unnamed vaccine,Unknown,Pre-clinical,No,11/03/2020,https://hms.harvard.edu/news/designing-coronavirus-vaccine,no,yes,NA
Royal (Wuxi) Biopharmaceutical ,China,Unnamed vaccine,Unknown,Pre-clinical,No,17/04/2020,https://www.biocentury.com/article/304515,no,no,NA
Shandong Buchang Pharma,China,Unnamed vaccine,Unknown,Pre-clinical,No,12/02/2020,https://fr.reuters.com/article/idUSP8N2A605E,no,no,NA
SmartPharm Therapeutics Inc/Sorrento Therapeutics,USA,Gene-encoded antibody vaccine,Unknown,Pre-clinical,No,23/03/2020,https://smartpharmtx.com/archives/7805,no,yes,NA
Tulane University,USA,Unnamed vaccine,Unknown,Pre-clinical,No,19/02/2020,https://news.tulane.edu/pr/tulane-university-launches-new-coronavirus-research-program-develop-vaccine-and-advanced,no,yes,NA
United Biomedical/c19,Taiwan/USA,Unnamed vaccine,Unknown,Pre-clinical,No,19/03/2020,http://www.unitedbiomedical.com/COVID-19/covid-19.html,no,yes,NA
Vault Pharma/University of California Los Angeles,USA,Unnamed vaccine,Unknown,Pre-clinical,No,01/06/2020,https://www.businesswire.com/news/home/20200601005170/en/Coronavirus-Vaccine-Development-Underway-Vault-Pharma,no,yes,Nanoparticles (vaults) as second-line defense of infection
Verndari Inc/UC Davis,USA,Unnamed vaccine,Unknown,Pre-clinical,No,29/04/2020,https://www.verndariinc.com/news/4,no,yes,VaxiPatch single-dose dermal patch with a metal microneedle array
Vir Biotechnology/GSK,USA/UK,Unnamed vaccine,Unknown,Pre-clinical,No,06/04/2020,https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus,no,yes,NA
Vivaldi Biosciences/Esco Aster,USA/Singapore,Unnamed vaccine,Unknown,Pre-clinical,No,14/05/2020,https://www.vivaldibiosciences.com/news-2/e4punpyr485q117deum1k1xrps4wjt,no,yes,Chimeric vaccine (coronavirus and influenza)
ZhongKe Biopharm ,China,Unnamed vaccine,Unknown,Pre-clinical,No,17/04/2020,https://www.biocentury.com/article/304515,no,no,NA
Zhongyi Anke Biotechnology ,China,Unnamed vaccine,Unknown,Pre-clinical,No,17/04/2020,https://www.biocentury.com/article/304515,no,no,NA
AIOVA,Unknown,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,16/12/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Lentivioral vector retro-VLP particles
Altimmune,USA,T-COVID,Vector (non-replicating),Pre-clinical,No,01/06/2020,https://www.globenewswire.com/news-release/2020/06/01/2041361/0/en/Altimmune-Launches-Clinical-Trial-of-T-COVIDTM-an-Investigational-Intranasal-Immune-Modulator-for-the-Treatment-of-Patients-with-Early-COVID-19.html,yes,no,Adenovirus-based NasoVAX
Altimmune/University of Alabama at Birmingham,USA,AdCOVID,Vector (non-replicating),Phase I,No,28/02/2020,https://www.globenewswire.com/news-release/2020/02/28/1992600/0/en/Altimmune-Completes-First-Development-Milestone-Toward-a-Single-Dose-Intranasal-COVID-19-Vaccine.html,no,yes,Adenovirus-based NasoVAX expressing SARS2-CoV spike protein
Ankara University,Turkey,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Adenovirus-based
Bharat Biotech,India,BBV154,Vector (non-replicating),Phase I,No,01/10/2020,https://www.bharatbiotech.com/intranasal-vaccine.html,no,no,Intranasal Chad-vectored vaccine
Bharat Biotech/Thomas Jefferson University,USA/India,CORAVAX,Vector (non-replicating),Pre-clinical,No,07/04/2020,https://www.beckershospitalreview.com/infection-control/thomas-jefferson-university-researchers-develop-covid-19-vaccine-candidate.html,yes,yes,Killed rabies carrier vaccine
CanSino Biological Inc/Beijing Institute of Biotechnology,China,Ad5-nCoV,Vector (non-replicating),Phase III,Yes,20/01/2020,https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials,yes,yes,NA
CanSino Biological Inc/PLA Academy of Military Sciences,China,Ad5-nCoV,Vector (non-replicating),Phase I,No,28/09/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Ad5 viral vector
Centro Nacional Biotecnología (CNB-CSIC)/(vector),Spain,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,26/03/2020,https://fems-microbiology.org/wp-content/uploads/2020/03/Enjuanes-Sola-Zúñiga-2020.-Novel-Human-Pathogenic-Coronavirus-SARS-CoV-2.pdf,yes,yes,MVA expressing structural proteins
Erciyes University (vector),Turkey,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,23/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Adeno5 based
Gamaleya Research Institute,Russia,Gam-COVID-Vac/Sputnik V,Vector (non-replicating),Phase III,Yes,01/06/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"rAd26/rAd5 expressing S protein, intramuscular, separate trial of lyophilised formulation"
GeoVax,China,MVA-VLP vaccine,Vector (non-replicating),Pre-clinical,No,27/01/2020,https://www.geovax.com/news/geovax-and-bravovax-wuhan-china-to-collaborate-on-development-of-coronavirus-vaccine,yes,yes,MVA-encoded VLP; formerly listed as GeoVax/BravoVax but collaboration did not proceed
German Center for Infection Research (DZIF)/IDT Biologika GmbH/Ludwig Maximilian University of Munich,Germany,MVA-SARS-2-S,Vector (non-replicating),Phase I,No,27/03/2020,https://www.en.uni-muenchen.de/news/newsarchiv/2020/sutter_impfstoffe_en.html,yes,no,Modified Caccinia virus Ankara vaccine
Globe Biotech Ltd (viral vector),Bangladesh,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Ad5 vector
Greffex,USA,Ad5 S (GREVAX),Vector (non-replicating),Pre-clinical,No,11/03/2020,https://www.greffex.com/news/greffex-inc-completes-covid-19-vaccine-and-prepares-for-testing/,yes,yes,Ad5 S (GREVAX platform)
Gritstone Oncology,USA,ChAdV68-S/SAM-LNP-S,Vector (non-replicating),Phase I,No,20/01/2021,https://ir.gritstoneoncology.com/news-releases/news-release-details/gritstone-and-genevant-sciences-announce-license-agreement-covid,yes,no,ChAd68 and self-amplifying mRNA (SAM) vectors expressing spike alone or spike plus additional T cell epitopes
Icahn School of Medicine at Mount Sinai (vector #1),USA,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,01/09/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Newcastle disease virus expressing S
Icahn School of Medicine at Mount Sinai (vector #2),USA,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,01/02/2021,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Newcastle disease virus expressing membrane-anchored spike
ID Pharma,Japan,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Sendai virus vector
IDIBAPS-Hospital Clinic (viral vector),Spain,MVA-S vaccine,Vector (non-replicating),Pre-clinical,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
ImmunityBio Inc/NantKwest Inc,USA,hAd5-S-Fusion+N-ETSD,Vector (non-replicating),Phase I,No,14/04/2020,https://www.biospace.com/article/releases/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter/,yes,yes,Four deletions enabling response in Ad-exposed
Institut Pasteur/TheraVectys,France,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,01/02/2020,http://www.theravectys.com/development-pipeline/,yes,yes,Intranasal lentiviral vector vaccine
Janssen Pharmaceutical Companies,USA,Ad26.COV2.S,Vector (non-replicating),Phase III,Yes,27/01/2020,https://www.cnbc.com/2020/01/27/jj-pretty-confident-it-can-create-china-coronavirus-vaccine.html,yes,yes,Ad26 (alone or with MVA boost)
Massachusetts Eye and Ear/Massachusetts General Hospital/AveXis,USA,AAVCOVID,Vector (non-replicating),Pre-clinical,No,05/05/2020,https://masseyeandear.org/news/press-releases/2020/05/mee-and-mgh-advancing-aavcovid-vaccine,yes,yes,"adeno-associated viral (AAV)-based, S protein"
McMaster University,Canada,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,26/05/2020,Direct contact,no,no,Multi-valent HuAd5 and ChAd68-vectored; aerosol delivery
National Center for Genetic Engineering &/Biotechnology (BIOTEC)/GPO,Thailand,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
"National Research Centre, Egypt (vector)",Egypt,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,30/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Influenza A H1N1 vector 
ReiThera/Leukocare/Univercells,Italy,GRAd-COV2,Vector (non-replicating),Phase II/III,No,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,Replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S
Stabilitech Biophaarma Ltd,UK,OraPro-COVID-19,Vector (non-replicating),Pre-clinical,No,19/03/2020,https://www.stabilitech.com/orapro-covid-19/,yes,yes,Orally administered recombinant adenovirus vector
Tsinghua University,China,Adenovirus-vectored vaccine,Vector (non-replicating),Pre-clinical,No,02/04/2020,http://www.china.org.cn/china/2020-04/02/content_75891534.htm,no,no,Adenovirus vector-based vaccine (could not verify if replicating/non-replicating)
University of Georgia/University of Iowa,USA,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Parainfluenza virus 5-based vaccine expressing S protein
University of Helsinki/University of Eastern Finland,Finland,Non-replicating viral vector vaccine,Vector (non-replicating),Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Ad5 vector intranasal 
University of Oxford/AstraZeneca,UK,ChAdOx1-S,Vector (non-replicating),Phase IV,Yes,10/01/2020,https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development,yes,yes,Chimpanzee adenovirus vector
University of South Australia/Sementis Ltd,Australia,SCV-S,Vector (non-replicating),Pre-clinical,No,01/05/2020,https://sementis.com.au,no,no,Spike antigen; Sementis Copenhagen Vector platform
Valo Therapeutics Ltd,Finland/USA,Pan-Corona,Vector (non-replicating),Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Adenovirus-based + HLA-matched peptides
Vaxart,USA,VXA-CoV2-1,Vector (non-replicating),Phase I,No,18/03/2020,http://www.globenewswire.com/news-release/2020/03/18/2002458/0/en/EMERGENT-BIOSOLUTIONS-SIGNS-DEVELOPMENT-AND-MANUFACTURING-AGREEMENT-WITH-VAXART-FOR-THEIR-EXPERIMENTAL-ORAL-VACCINE-CANDIDATE-FOR-CORONAVIRUS-DISEASE.html,yes,yes,NA
Vaxinz Inc/Institute Leloir Foundation/CONICET/(vector #1),Argentina/USA,VXZ-11NS,Vector (non-replicating),Pre-clinical,No,01/08/2020,http://vaxinz.com,no,no,Direct contact; human adenoviral vector
Vaxinz Inc/Institute Leloir Foundation/CONICET/(vector #2),Argentina/USA,VXZ-11PFS,Vector (non-replicating),Pre-clinical,No,01/08/2020,http://vaxinz.com,no,no,Direct contact; human adenoviral vector
Aurobindo,India,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,15/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,VSV-S
BIOCAD/IEM,Russia,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,11/04/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)
Cellid Co Ltd/IAVI,Republic of Korea,AdCLD-CoV19,Vector (replicating),Phase I/II,No,05/01/2021,https://www.eurekalert.org/pub_releases/2021-01/ivi-cie010421.php,yes,yes,
City of Hope,USA,COH04S1,Vector (replicating),Phase I,No,24/03/2020,https://www.cityofhope.org/breakthroughs/city-of-hope-researchers-developing-covid-19-vaccine,no,no,Synthetic MVA-based vaccine
Farmacológicos Veterinarios SAC/Universidad Peruana Cayetano Heredia/(viral vector #1),Peru,rNDV-LS1-HN-RBD,Vector (replicating),Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing RBD
Farmacológicos Veterinarios SAC/Universidad Peruana Cayetano Heredia/(viral vector #2),Peru,rNDV-LS1-S1-F,Vector (replicating),Pre-clinical,No,15/01/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,Intranasal Newcastle disease virus vector (rNDV-FARVET) expressing S1
Fundação Oswaldo Cruz (FIOCRUZ)/Instituto Buntantan,Brazil,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,01/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Attenuated Influenza expressing an antigenic portion of the Spike protein
German Center for Infection Research (DZIF)/CanVirex AG,Germany,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,26/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF,yes,yes,"Measles virus (S, N targets)"
IAVI/Merck,USA,V590,Vector (replicating),Terminated,No,05/03/2020,https://www.iavi.org/newsroom/press-releases/2020/iavi-and-batavia-announce-collaboration-vsv-vector-epidemic-preparedness-vaccines,yes,yes,Replication-competent VSV chimeric virus technology (VSVdeltaG) expressing Spike (S) glycoprotein
Institut Pasteur/Themis/University of Pittsburg/Merck,France/USA/Austria,V591/TMV-083,Vector (replicating),Terminated,No,19/03/2020,https://www.themisbio.com/cepi-collaborates-with-the-institut-pasteur-in-a-consortium-to-develop-covid-19-vaccine/,yes,yes,Measles Vector
Intravacc/Wageningen Bioveterinary Research/Utrecht University,Netherlands/Germany,NDV-SARS-CoV-2/Spike ,Vector (replicating),Pre-clinical,No,14/05/2020,https://www.intravacc.nl/,yes,yes,NA
Israel Institute for Biological Research/Weizmann Institute of Science,Israel,rVSV-SARS-CoV-2-S,Vector (replicating),Phase I/II,No,28/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,VSV-S
KU Leuven,Belgium,YF17D vector vaccine,Vector (replicating),Pre-clinical,No,27/01/2020,https://www.brusselstimes.com/all-news/belgium-all-news/92085/ku-leuven-researchers-near-test-phase-for-coronavirus-vaccine-wuhan-china-infection-virus-france/,yes,yes,Yellow fever vaccine backbone with SARS-CoV-2 spike protein
Lancaster University,UK,APM vector vaccine,Vector (replicating),Pre-clinical,No,15/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Avian paramyxovirus vector (APMV) 
Sumagen/International Vaccine Institute,Republic of Korea,VSV vector vaccine,Vector (replicating),Pre-clinical,No,06/03/2020,https://pulsenews.co.kr/view.php?year=2020&no=237416,no,no,VSV vector
Tonix Pharma/Southern Research,USA,Horsepox vector vaccine,Vector (replicating),Pre-clinical,No,24/03/2020,https://ir.tonixpharma.com/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year,yes,yes,Horsepox vector expressing S protein
University of Hong Kong/Jiangsu Provincial CDC/Beijing Wantai Biological Pharmacy/Xiamen University,China,DelNS1-2019-nCoV-RBD-OPT1,Vector (replicating),Phase II,No,09/09/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Intranasal flu-based-RBD
University of Manitoba (vector),Canada,Dendritic cell-targeting viral vector vaccine,Vector (replicating),Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
University of Western Ontario,Canada,VSV-S,Vector (replicating),Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Replicating viral vector; VSV-S
UW-Madison/FluGen/Bharat Biotech,USA/India,CoroFlu,Vector (replicating),Pre-clinical,No,02/04/2020,https://www.pharmaceutical-technology.com/news/flugen-bharat-bio-uw-madison-covid-vaccine/,yes,yes,M2SR platform; self-limiting replication; intranasal
Vector Institute (vector #1),Russia,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Measles Vector
Vector Institute (vector #2),Russia,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Recombinant vaccine based on Influenza A virus, intranasal vaccine"
Vector Institute (vector #3),Russia,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Replicating viral vector; VSV vector
Zydus Cadila Healthcare Limited (vector),India,Replicating viral vector vaccine,Vector (replicating),Pre-clinical,No,20/03/2020,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,yes,yes,Measles vector
Arizona State University (VLP #1),USA,VLP vaccine,Virus-like particle,Pre-clinical,No,12/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Myxoma virus co-expressing S, M, N and E proteins"
Arizona State University (VLP #2),USA,VLP vaccine,Virus-like particle,Pre-clinical,No,12/02/2021,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,"Plasmid driven production of VLPs containing S, M, N and E proteins"
ARTES Biotechnology,Germany,VLP vaccine,Virus-like particle,Pre-clinical,No,27/04/2020,http://artes-biotechnology.biz/artes-joins-global-combat-against-corona/,yes,yes,NA
Bezmialem Vakif University,Turkey,VLP vaccine,Virus-like particle,Pre-clinical,No,21/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Doherty Institute,Australia,VLP vaccine,Virus-like particle,Pre-clinical,No,28/01/2020,https://www.doherty.edu.au/our-work/institute-themes/viral-infectious-diseases/emerging-infections/2019-novel-coronavirus/about-2019-novel-coronavirus,yes,yes,NA
Icosavax,USA,VLP vaccine,Virus-like particle,Pre-clinical,No,30/10/2020,https://www.icosavax.com/post/icosavax-launches-covid-19-vaccine-program-with-preclinical-data-and-16-5-million-in-new-funding,no,yes,Displaying SARS-CoV-2 RBD
Imophoron Ltd/Bristol University,UK,ADDomer VLP vaccine,Virus-like particle,Pre-clinical,No,08/03/2020,https://www.pharmaceutical-technology.com/news/bristol-university-imophoron-covid-vaccine/,yes,yes,ADDomer multiepitope display
IrsiCaixa AIDS Research/IRTA-CReSA/Barcelona Supercomputing Centre/Grifols,Spain,VLP vaccine,Virus-like particle,Pre-clinical,No,28/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,S protein integrated in HIV VLPs
Mahidol University/GPO,Thailand,VLP vaccine,Virus-like particle,Pre-clinical,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Max Planck Institute,Germany,VLP vaccine,Virus-like particle,Pre-clinical,No,25/07/2020,https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
Medicago Inc,Canada/USA/UK,CoVLP,Virus-like particle,Phase II/III,No,12/03/2020,https://www.biospace.com/article/releases/medicago-announces-production-of-a-viable-vaccine-candidate-for-covid-19/,yes,yes,VLP (CoVLP) adjuvanted with GSK or Dynavax adjuvants
Middle East Technical University,Turkey,VLP vaccine,Virus-like particle,Pre-clinical,No,01/07/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
Navarrabiomed Oncoimmunology group,Spain,VLP vaccine,Virus-like particle,Pre-clinical,No,01/06/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,Lentivirus and baculovirus vehicles 
OSIVAX,France,VLP vaccine,Virus-like particle,Pre-clinical,No,05/05/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,VLP (COVID-19 and SARS1)
Saiba GmbH,Switzerland,VLP vaccine,Virus-like particle,Pre-clinical,No,11/04/2020,https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1,yes,yes,RBD displayed on VLPs
Shiraz University,Iran,Plant-based vaccine,Virus-like particle,Pre-clinical,No,12/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,NA
SpyBiotech/Accelagen Pty/Serum Institute of India,UK/Australia/India,RBD-HBsAg VLP vaccine,Virus-like particle,Phase I/II,No,05/06/2020,https://www.gov.uk/government/news/india-joins-uks-global-vaccine-mission,yes,yes,SpyCatcher/SpyTag display technology
SpyBiotech/University of Oxford/Pirbright Institute,UK,RBD-SpyVLP,Virus-like particle,Pre-clinical,No,07/09/2020,https://www.spybiotech.com/news/covid-19-vaccine-candidate-using-spytagspycatcher-/,no,no,SpyCatcher/SpyTag display technology
Tampere University (VLP),Finland,VLP vaccine,Virus-like particle,Pre-clinical,No,29/10/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,no,VLPs produced in BEVS
University of Manitoba (VLP),Canada,Dendritic cell-targeting VLP vaccine,Virus-like particle,Pre-clinical,No,09/11/2020,https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines,yes,yes,NA
University of Sao Paulo,Brazil,VLP vaccine,Virus-like particle,Pre-clinical,No,18/03/2020,https://www.efe.com/efe/english/portada/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine/50000260-4199376,yes,yes,NA
VBI Vaccines/National Research Council of Canada,USA,VBI-2902a,Virus-like particle,Phase I/II,No,31/03/2020,https://www.businesswire.com/news/home/20200331005198/en/VBI-Vaccines-Announces-Collaboration-National-Research-Council,yes,yes,"Enveloped VLP pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS S proteins"